Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2009

Filing Date
Filed February 19, 2010
Period End
December 31, 2009
Security
IDXX
One revenue dollarkept$0.12
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 19, 2010. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2009 10-K shows a company that grew revenue modestly in a weak economy while sustaining solid profitability and returning capital to shareholders.

Total revenue rose 0.7% to $1,031.6 milliona (about 2.4% lower on a currency- and acquisition-adjusted basis), while operating income increased 2.0% to $176.0 million and diluted EPS rose 7.5% to $2.01. Growth was concentrated in the Companion Animal Group (CAG), where the Catalyst Dx chemistry analyzer drove instrument and consumables sales, offset by weaker rapid assay pricing, reduced patient visits, and the loss of higher-margin pharmaceutical revenue following the 2008 divestiture. Gross margin compressed slightly to 51.0% from 51.7%, and Water and Other segments were the bright spots on margin and profit.

Balance sheet and cash flow improved meaningfully. Operating cash flow rose to $175.0 millionb from $143.3 million, and total debt fell from $156.5 million to $123.9 million, with the revolver balance dropping to $118.8 million. IDEXX repurchased $83.1 million of stock (1.9 million shares) and ended the year with $106.7 million in cash.

Capital spending of $49.4 millionc was lower than 2008 as the Westbrook, Maine headquarters expansion moves toward completion in 2011; 2010 capex is planned at about $45 million. Key investor watch items include an FTC investigation (announced January 2010) into companion animal pricing and distribution practices, concentration risk with distributors (Butler Schein Animal Health is 7% of revenue after the December 2009 merger), single-site manufacturing in Westbrook, Maine, and the expected expiration of the SNAP FIV/FeLV patent in June 2009 that could pressure those product margins. Management also flagged near-term gross margin pressure from higher instrument placements and the phase-out of rapid assay Practice Developer rebates, and an EU BSE testing age change that will reduce post-mortem test volumes.

Key Highlights

  1. Revenue rose 0.7% to $1,031.6M; organic growth was about -2.4% after currency (-1.6%) and acquisition/divestiture effects, reflecting a weak economy and the 2008 pharmaceutical divestiture.
  2. Operating income grew 2.0% to $176.0M (17.1% margin, up from 16.8%) and diluted EPS increased 7.5% to $2.01, helped by a 2.0% reduction in operating expenses.
  3. Gross margin declined to 51.0% from 51.7%, pressured by mix shift toward lower-margin instruments and services, higher overhead, and the absence of pharmaceutical sales.
  4. Operating cash flow increased 22% to $175.0M, and total debt fell to $123.9M from $156.5M while the company retained $106.7M in cash.
  5. The company repurchased $83.1M of stock in 2009 (1.9M shares) under a 44M-share authorization of which about 6.3M remained, and it has never paid a cash dividend.
  6. Regulatory and legal risk increased: in January 2010 the FTC opened an investigation into IDEXX's companion animal pricing and marketing practices, and the company expects a subpoena.
  7. Customer and product concentration remains: Butler (now part of Butler Schein Animal Health) represented 7% of revenue, distributors sell substantially all U.S. rapid assays and consumables, and the Westbrook, Maine site produces most products.

Follow one dollar

Of each $1.00 of revenue in FY2009, IDEXX Laboratories kept $0.12.

  1. Revenue$1.03B100.0%
  2. Cost of revenue−$505.4M49.0%
  3. Gross profit$526.3M51.0%
  4. Operating costs−$350.3M34.0%
  5. Operating income$176.0M17.1%
  6. Interest, other & tax−$53.7M5.2%
  7. Net income$122.2M11.8%
Computed from 10-KFY2009filed February 19, 2010Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2009 revenue went

$1.03B
  • Cost of revenue: $505.4M, 49% of revenue
  • Other operating costs: $285.2M, 28% of revenue
  • Net income: $122.2M, 12% of revenue
  • R&D: $65.1M, 6.3% of revenue
  • Interest, other & tax: $53.7M, 5.2% of revenue

Kept 12% as net income

Full revenue history →

Financial Statements

FY2009 against FY2008

Line itemFY2009FY2008Change
Revenue$1.03B$1.02B+0.7%
Cost of Revenue$505.35M$494.26M+2.2%
Gross Profit$526.28M$529.77M−0.7%
R&D Expenses$65.12M$70.67M−7.9%
Operating Income$175.97M$172.46M+2.0%
Interest Expense$1.92M$4.59M−58.2%
Net Income$122.22M$116.17M+5.2%
EPS (Basic)$1.04$0.97+7.2%
EPS (Diluted)$1.00$0.94+7.5%
Shares Outstanding (Basic)117.62M119.91M−1.9%
Shares Outstanding (Diluted)121.36M124.50M−2.5%

Frequently Asked Questions

  1. How did IDEXX perform financially in 2009 and what drove the results?

    Revenue grew 0.7% to $1,031.6M, but on a constant-currency, organic basis sales declined about 2.4%. Catalyst Dx analyzer placements and related consumables drove growth in instruments and consumables (+4.4%) and laboratory services (+3.5%), while the loss of the pharmaceutical business and weaker demand from reduced pet visits offset some of that. Net income rose 5.2% to $122.2M, and diluted EPS rose to $2.01 from $1.87.

  2. Is IDEXX's balance sheet and cash generation strong enough to fund its strategy?

    Yes. Operating cash flow of $175.0M comfortably funded $49.4M in capex and $83.1M in buybacks, with leftover cash used to reduce debt. Year-end cash was $106.7M and $80.2M of revolver capacity remained. Management believes resources are sufficient for the next twelve months, though the company noted that borrowing costs would likely be higher in the current credit market.

  3. What are the biggest risks investors should weigh from this filing?

    The most significant items are the FTC investigation into companion animal practices, concentration among U.S. distributors (Butler Schein), single-facility manufacturing risk in Westbrook, Maine, and increased competition from larger diagnostics companies and VCA Antech's reference labs. Product-specific risks include the June 2009 expiration of the SNAP FIV/FeLV patent, which could lower margins on those tests, and the EU's raised BSE testing age, which reduces post-mortem test volumes. Gross margin is also expected to face near-term pressure from heavier instrument placements.

  4. What is the outlook for capital spending and shareholder returns?

    Management planned about $45M of capital expenditures in 2010, including roughly $12M for the Westbrook expansion (expected to finish in Q2 2011) and about $10M for IT. Share repurchases are expected to continue as management views buybacks as a favorable investment and as a way to offset dilution from equity compensation. The company has no present intention to pay dividends.